P. Vandepapelière

发表

Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.

Guido Ferrari, Sharon Frey, M Juliana McElrath, 2007, Vaccine.

12 – THERAPEUTIC VACCINES FOR CONTROL OF HUMAN PAPILLOMAVIRUS CHRONIC INFECTIONS

P. Vandepapelière, 2000 .

Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults

G. Leroux-Roels, G. Dubin, M. Fourneau, 2013, Human vaccines & immunotherapeutics.

Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B‐related disease

P. Neuhaus, J. Vollmar, P. Vandepapelière, 2003, Hepatology.

Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical Trial

X. Mariette, P. Miranda, P. Durez, 2014, PloS one.

A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.

E. Ledent, G. Leroux-Roels, T. Heineman, 2012, The Journal of infectious diseases.

Randomized Controlled Study of the Safety and Immunogenicity of Pneumococcal Vaccine Formulations Containing PhtD and Detoxified Pneumolysin with Alum or Adjuvant System AS02V in Elderly Adults

J. Poolman, P. Vandepapelière, A. Nilsson, 2014, Clinical and Vaccine Immunology.

Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers.

Y. Poovorawan, A. Safary, P. Vandepapelière, 1992, The Pediatric infectious disease journal.

Immune response to a combined hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine administered to infants at 2, 4 and 6 months of age.

J. Arístegui, P. Vandepapelière, A. Pérez, 1997, Vaccine.

Evaluation of a combined tetravalent diphtheria, tetanus, whole-cell pertussis and hepatitis B candidate vaccine administered to healthy infants according to a three-dose vaccination schedule.

A. Safary, P. Vandepapelière, G. Papaevangelou, 1995, Vaccine.

The Immunogenicity and Reactogenicity of Combined Tetravalent Diphtheria, Tetanus, Pertussis, and Hepatitis B Vaccine in Infants

A. Theamboonlers, Y. Poovorawan, A. Safary, 1994 .

Immunogenicity and reactogenicity of a combined DTPw-hepatitis B vaccine in Lithuanian infants

V. Usonis, P. Vandepapelière, D. Taylor, 1996, European Journal of Pediatrics.

Next-generation intranasal Covid-19 vaccine: a polymersome-based protein subunit formulation that provides robust protection against multiple variants of concern and early reduction in viral load of the upper airway in the golden Syrian hamster model

Devendra Shivhare, Gaurav Sinsinbar, P. Vandepapelière, 2022, bioRxiv.

Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.

G. Lau, G. Leroux-Roels, E. Gane, 2007, Vaccine.

Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system.

P. van Damme, G. Leroux-Roels, A. Meheus, 1998, Vaccine.

Randomized, single-blind comparison of the immunogenicity and reactogenicity of 20 micrograms and 10 micrograms doses of hepatitis B vaccine in adolescents.

A. Theamboonlers, Y. Poovorawan, A. Safary, 1993, The Southeast Asian journal of tropical medicine and public health.

Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine

Devendra Shivhare, Gaurav Sinsinbar, P. Vandepapelière, 2022, ACS nano.

Acute and chronic effects of lisinopril on renal and systemic hemodynamics in hypertension

J. Degaute, M. Leeman, P. Vandepapelière, 1992, Cardiovascular Drugs and Therapy.

9 – THERAPEUTIC VACCINES FOR CONTROL OF HERPES SIMPLEX VIRUS CHRONIC INFECTIONS

P. Vandepapelière, 2000 .

Active immunisation of human interferon α transgenic mice with a human interferon α Kinoid induces antibodies that neutralise interferon α in sera from patients with systemic lupus erythematosus

J. Piette, M. Hoekman, Z. Amoura, 2011, Annals of the rheumatic diseases.

Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination.

C. Meijer, J. Walboomers, L. Stanberry, 2005, The Journal of infectious diseases.

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

G. Leroux-Roels, E. Hanon, P. Moris, 2008, Vaccine.

14 – THERAPEUTIC VACCINES FOR CHRONIC HEPATITIS B INFECTION

P. Vandepapelière, 2000 .

Heat stability of a recombinant DNA hepatitis B vaccine.

P. van Damme, A. Meheus, A. Safary, 1992, Vaccine.

Glycoprotein-D-adjuvant vaccine to prevent genital herpes.

F. Aoki, D. Bernstein, L. Stanberry, 2002, The New England journal of medicine.

Therapeutic vaccination against chronic viral infections.

P. Vandepapelière, 2002, The Lancet. Infectious diseases.

Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.

M. Altfeld, G. Leroux-Roels, M. Janssens, 2010, Vaccine.

The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study.

Pierre Vandepapelière, François Spertini, Erik Jongert, 2013, Tuberculosis.

Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults.

B. Rehermann, G. Leroux-Roels, P. Moris, 2005, Vaccine.

Safety, Immunogenicity and Clinical Phase I-II Results of TNFα-Kinoid Immunotherapeutic in Crohn's Disease Patients

G. Rogler, B. Fanget, F. Kruger, 2011 .

Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.

I. Carletti, G. Leroux-Roels, M. Janssens, 2015, Vaccine.

Induction of Strong HIV-1–Specific CD4+ T-Cell Responses Using an HIV-1 gp120/NefTat Vaccine Adjuvanted With AS02A in Antiretroviral-Treated HIV-1–Infected Individuals

M. Altfeld, M. Demoitié, T. Flynn, 2012, Journal of acquired immune deficiency syndromes.

Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid.

Eric Hachulla, Pierre Vandepapelière, Bernard Fanget, 2013, Arthritis and rheumatism.

Su2091 Results of a Phase II, Randomized, Double Blind, Controlled Trial of the Efficacy of Active Therapeutic Immunization With TNF-Kinoid in Patients With Moderate to Severe Crohn's Disease With Secondary Resistance to TNFα Antagonist

O. Dewit, P. Rutgeerts, S. Vermeire, 2012 .

Safety and efficacy of lisinopril in elderly patients with mild to moderate hypertension.

P. Vandepapelière, R. Marlier, G. De Vriese, 1989, Journal of human hypertension.

Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study

Julie Ducreux, Pierre Vandepapelière, Thérèse Croughs, 2016, Rheumatology.

Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials.

Pierre Vandepapelière, Jeanne-Marie Devaster, G. Leroux-Roels, 2015, Vaccine.

First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes

K. Owen, C. Boitard, M. Kindermans, 2023, BMC Medicine.

Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.

M. Altfeld, G. Leroux-Roels, M. Janssens, 2010, Vaccine.